BNGO Bionano Genomics, Inc.

Overview and Growth

Fiscal 2025 results for Bionano Genomics, Inc. combined $28.51M of revenue with net loss of $26.39M and an operating cash outflow of $16.34M. At $28.51M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Compared with $30.78M in fiscal 2024, revenue decreased 7.4%, a top-line contraction that reduced operating scale. On a per-share basis, diluted EPS was -$4.85, which connects the reported earnings outcome with the company’s diluted share count. A diluted share base of 5.45M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 1.27M diluted shares in fiscal 2024, the current 5.45M base was 328.4% higher. Total assets stood at $73.58M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Revenue equaled 0.39x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

After reported cost of revenue, the company retained $13.19M as gross profit before recognizing operating expenses and other items. Gross profit represented 46.3% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $33.34M, reflecting costs that exceeded gross profit. The operating loss equaled 116.9% of revenue, showing the scale of the operating deficit relative to sales. After all below-operating-line items, the company recorded a net loss of $26.39M for the fiscal year. Measured against revenue, the bottom-line deficit represented 92.6% after all recognized items. EBITDA was negative $23.81M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $26.33M, establishing the deficit before tax effects. Measured against revenue, the pretax deficit represented 92.4%. The reported income-tax provision was $67.00K, the amount recognized between pretax income and the final net-income result. Relative to period-end equity, the net loss represented 59.4%. The loss-to-assets relationship was 35.9%, placing the bottom-line deficit against the company’s resource base. The net loss narrowed to $26.39M from $112.02M in fiscal 2024.

Liquidity and Capital Structure

Total assets were $73.58M, supported by $29.16M of liabilities and $44.42M of shareholder equity. The near-term balance sheet paired $45.39M of current assets with $22.94M of current liabilities at the reporting date. Current assets covered current liabilities by 1.98x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $2.99M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 13.0%, excluding receivables and other current assets. Book equity represented 60.4% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 39.6% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 4.1%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 4.0% from $76.67M in fiscal 2024, leaving current total assets lower year over year. Against $35.38M of equity in fiscal 2024, the current book-equity balance moved 25.6% and ended higher. Compared with $9.17M in fiscal 2024, the current cash balance moved 67.4% and finished lower.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $16.34M, rather than cash generation from operations. Compared with a $68.92M operating cash outflow in fiscal 2024, the current outflow improved to $16.34M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.